Free shipping on all orders over $ 500

Mirvetuximab soravtansine

Cat. No. M40544
Mirvetuximab soravtansine Structure
Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Mirvetuximab soravtansine is an antibody-drug concatenation (ADC) containing a folate receptor alpha (frα)-conjugated antibody, a cleavable junction, and the medenosine alkaloid DM4, a potent microtubulin-targeting agent, that can be used in studies related to platinum-resistant epithelial ovarian cancer (EOC).

Chemical Information
Molecular Weight 977.59
Formula C42H61ClN4O14S3
CAS Number 1453084-37-1
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Lucy Gilbert et al. Gynecol Oncol. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

[2] Ursula A Matulonis et al. J Clin Oncol. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

[3] Young-A Heo. Drugs. Mirvetuximab Soravtansine: First Approval

[4] K N Moore et al. Ann Oncol. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Related ADC Linker Products
DBCO-acid

DBCO-acid is a cleavable ADC linker used in the synthesis of ADC linker DBCO-NHS ester, and agent-linker conjugates DBCO-PEG-MMAE.

Boc-Gly-Gly-Phe-Gly-OH TFA

Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

Boc-Gly-Gly-Phe-Gly-OH

Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

Fomc-Gly-Gly-Phe-Gly-OH

Fomc-Gly-Gly-Phe-Gly-OH can be used as an intermediate in the synthesis of ADC dual-drug-linker.

Mc-Gly-Gly-Phe-Gly-PAB-OH

Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

  Catalog
Abmole Inhibitor Catalog




Keywords: Mirvetuximab soravtansine supplier, ADC Linker, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.